Use of nonobese diabetic mice to understand human type 1 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 3, 2010, Pages 541-561

  Thayer, Terri C ^a,b   Wilson, S Brian ^a   Mathews, Clayton E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Immunology; NOD mouse; Type 1 diabetes

Indexed keywords

ABATACEPT; ANTIDIABETIC AGENT; AUTOANTIBODY; AUTOANTIGEN; CD3 ANTIBODY; CD86 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INSULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL THERAPY; CLINICAL TRIAL; DENDRITIC CELL; DIABETOGENESIS; DISEASE COURSE; DISEASE MODEL; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; REVIEW;

ANIMALIA; CANIS FAMILIARIS; MUS;

EID: 77955756080     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.05.001     Document Type: Review

References (136)

1. Like A.A., Butler L., Williams R.M., et al. Spontaneous autoimmune diabetes mellitus in the BB rat. Diabetes 1982, 31:7-13.
2. Like A.A., Kislauskis E., Williams R.R., et al. Neonatal thymectomy prevents spontaneous diabetes mellitus in the BB/W rat. Science 1982, 216:644-646.
3. Makino S., Kunimoto K., Muraoka Y., et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980, 29:1-13.
4. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 1999, 5:601-604.
5. Roep B.O., Atkinson M. Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 2004, 47:1650-1656.
6. Roep B.O., Atkinson M., von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004, 4:989-997.
7. Willcox A., Richardson S.J., Bone A.J., et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009, 155:173-181.
8. Foulis A.K., Liddle C.N., Farquharson M.A., et al. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986, 29:267-274.
9. Hanafusa T., Imagawa A. Insulitis in human type 1 diabetes. Ann N Y Acad Sci 2008, 1150:297-299.
10. Bouma G., Coppens J.M., Mourits S., et al. Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. Eur J Immunol 2005, 35:2386-2396.
11. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997, 7:727-738.
12. Pirot P., Cardozo A.K., Eizirik D.L. Mediators and mechanisms of pancreatic β-cell death in type 1 diabetes. Arq Bras Endocrinol Metabol 2008, 52:156-165.
13. Abiru N., Yu L., Miao D., et al. Transient insulin autoantibody expression independent of development of diabetes: comparison of NOD and NOR strains. J Autoimmun 2001, 17:1-6.
14. Robles D.T., Eisenbarth G.S., Dailey N.J., et al. Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes 2003, 52:882-886.
15. Radillo O., Nocera A., Leprini A., et al. Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Clin Immunol Immunopathol 1996, 79:217-223.
16. Jansen A., Homo-Delarche F., Hooijkaas H., et al. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β-cell destruction in NOD mice. Diabetes 1994, 43:667-675.
17. Kolb H., Kantwerk G., Treichel U. Prospective analysis of islet lesions in BB rats. Diabetologia 1986, 29:A559.
18. Lee K.U., Amano K., Yoon J.W. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 1988, 37:989-991.
19. Jun H.S., Yoon C.S., Zbytnuik L., et al. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999, 189:347-358.
20. de Jersey J., Snelgrove S.L., Palmer S.E., et al. B cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice. Proc Natl Acad Sci U S A 2007, 104:1295-1300.
21. Clare-Salzler M.J., Brooks J., Chai A., et al. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992, 90:741-748.
22. Lo J., Clare-Salzler M.J. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev 2006, 5:419-423.
23. Papaccio G., Nicoletti F., Pisanti F.A., et al. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology 2000, 141:1500-1505.
24. Pasquali L., Giannoukakis N., Trucco M. Induction of immune tolerance to facilitate β cell regeneration in type 1 diabetes. Adv Drug Deliv Rev 2008, 60:106-113.
25. Christianson S.W., Shultz L.D., Leiter E.H. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993, 42:44-55.
26. Barrett J.C., Clayton D.G., Concannon P., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009, 41:703-707.
27. *0303). Hum Immunol 1999, 60:1227-1236.
28. Antoniou A.N., Elliott J., Rosmarakis E., et al. MHC class II Ab diabetogenic residue 57 Asp/non-Asp dimorphism influences T-cell recognition and selection. Immunogenetics 1998, 47:218-225.
29. Howson J.M., Walker N.M., Clayton D., et al. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009, 11(Suppl 1):31-45.
30. *0302. Diabetes 1997, 46:1888-1892.
31. Bennett S.T., Wilson A.J., Esposito L., et al. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. The IMDIAB Group. Nat Genet 1997, 17:350-352.
32. Asano K., Ikegami H., Fujisawa T., et al. The gene for human IL-21 and genetic susceptibility to type 1 diabetes in the Japanese. Ann N Y Acad Sci 2006, 1079:47-50.
33. Bergholdt R., Brorsson C., Boehm B., et al. No association of the IRS1 and PAX4 genes with type I diabetes. Genes Immun 2009, 10(Suppl 1):S49-S53.
34. Ghandil P., Chelala C., Dubois-Laforgue D., et al. Crohn's disease associated CARD15 (NOD2) variants are not involved in the susceptibility to type 1 diabetes. Mol Genet Metab 2005, 86:379-383.
35. Howson J.M., Walker N.M., Smyth D.J., et al. Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun 2009, 10(Suppl 1):S74-S84.
36. Smyth D.J., Howson J.M., Payne F., et al. Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med Genet 2006, 7:20.
37. Zhang Y., Xiao X., Liu Y., et al. The association of the PAX4 gene with type 1 diabetes in Han Chinese. Diabetes Res Clin Pract 2008, 81:365-369.
38. Eller E., Vardi P., Daly M.J., et al. IDDM17: polymorphisms in the AMACO gene are associated with dominant protection against type 1A diabetes in a Bedouin Arab family. Ann N Y Acad Sci 2004, 1037:145-149.
39. Bassuny W.M., Ihara K., Matsuura N., et al. Association study of the NRAMP1 gene promoter polymorphism and early-onset type 1 diabetes. Immunogenetics 2002, 54:282-285.
40. Takahashi K., Satoh J., Kojima Y., et al. Promoter polymorphism of SLC11A1 (formerly NRAMP1) confers susceptibility to autoimmune type 1 diabetes mellitus in Japanese. Tissue Antigens 2004, 63:231-236.
41. Sanjeevi C., Miller E., Dabadghao P., et al. Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. Clin Sci 2001, 43:1397-1404.
42. Uchigata Y., Okada T., Gong J.S., et al. A mitochondrial genotype associated with the development of autoimmune-related type 1 diabetes. Diabetes Care 2002, 25:2106.
43. Kissler S., Stern P., Takahashi K., et al. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat Genet 2006, 38:479-483.
44. Mathews C.E., Suarez-Pinzon W.L., Baust J.J., et al. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol 2005, 175:1248-1256.
45. Prochazka M., Leiter E.H., Serreze D.V., et al. Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science 1987, 237:286-289.
46. Wicker L.S., Miller B.J., Coker L.Z., et al. Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse. J Exp Med 1987, 165:1639-1654.
47. Mathews C.E., Graser R.T., Bagley R.J., et al. Genetic analysis of resistance to type-1 diabetes in ALR/Lt mice, a NOD-related strain with defenses against autoimmune-mediated diabetogenic stress. Immunogenetics 2003, 55:491-496.
48. McAleer M.A., Reifsnyder P., Palmer S.M., et al. Crosses of NOD mice with the related NON strain. A polygenic model for IDDM. Diabetes 1995, 44:1186-1195.
49. von Herrath M., Nepom G.T. Animal models of human type 1 diabetes. Nat Immunol 2009, 10:129-132.
50. Yui M.A., Muralidharan K., Moreno-Altamirano B., et al. Production of congenic mouse strains carrying NOD-derived diabetogenic genetic intervals: an approach for the genetic dissection of complex traits. Mamm Genome 1996, 7:331-334.
51. Acha-Orbea H., McDevitt H.O. The first external domain of the nonobese diabetic mouse class II I-A β chain is unique. Proc Natl Acad Sci U S A 1987, 84:2435-2439.
52. Ridgway W.M., Fasso M., Fathman C.G. A new look at MHC and autoimmune disease. Science 1999, 284:749. 751.
53. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996, 85:291-297.
54. Wong F.S., Wen L. What can the HLA transgenic mouse tell us about autoimmune diabetes?. Diabetologia 2004, 47:1476-1487.
55. Rajagopalan G., Kudva Y.C., Chen L., et al. Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the β cells of islets of Langerhans. Int Immunol 2003, 15:1035-1044.
56. Wen L., Wong F.S., Tang J., et al. In vivo evidence for the contribution of human histocompatibility leukocyte antigen (HLA)-DQ molecules to the development of diabetes. J Exp Med 2000, 191:97-104.
57. *0201 transgenic NOD mice. Diabetes 2007, 56:2551-2560.
58. Marron M.P., Graser R.T., Chapman H.D., et al. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci U S A 2002, 99:13753-13758.
59. Pomerleau D.P., Bagley R.J., Serreze D.V., et al. Major histocompatibility complex-linked diabetes susceptibility in NOD/Lt mice: subcongenic analysis localizes a component of Idd16 at the H2-D end of the diabetogenic H2(g7) complex. Diabetes 2005, 54:1603-1606.
60. Hattori M., Yamato E., Itoh N., et al. Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. J Immunol 1999, 163:1721-1724.
61. Brims D.R., Qian J., Jarchum I., et al. Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect. Int Immunol 2010, 22:191-203.
62. Hamilton-Williams E.E., Serreze D.V., Charlton B., et al. Transgenic rescue implicates β2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc Natl Acad Sci U S A 2001, 98:11533-11538.
63. Mathews C.E., Leiter E.H., Spirina O., et al. mt-Nd2 Allele of the ALR/Lt mouse confers resistance against both chemically induced and autoimmune diabetes. Diabetologia 2005, 48:261-267.
64. Gusdon A.M., Votyakova T.V., Mathews C.E. mt-Nd2a suppresses reactive oxygen species production by mitochondrial complexes I and III. J Biol Chem 2008, 283:10690-10697.
65. Gusdon A.M., Votyakova T.V., Reynolds I.J., et al. Nuclear and mitochondrial interaction involving mt-Nd2 leads to increased mitochondrial reactive oxygen species production. J Biol Chem 2007, 282:5171-5179.
66. Chen J., Gusdon A.M., Thayer T.C., et al. Role of increased ROS dissipation in prevention of T1D. Ann N Y Acad Sci 2008, 1150:157-166.
67. Chen J., Lu Y., Lee C.H., et al. Commonalities of genetic resistance to spontaneous autoimmune and free radical-mediated diabetes. Free Radic Biol Med 2008, 45:1263-1270.
68. Araki M., Chung D., Liu S., et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol 2009, 183:5146-5157.
69. Vafiadis P., Bennett S.T., Todd J.A., et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997, 15:289-292.
70. Geenen V. Thymus-dependent T cell tolerance of neuroendocrine functions: principles, reflections, and implications for tolerogenic/negative self-vaccination. Ann N Y Acad Sci 2006, 1088:284-296.
71. Chentoufi A.A., Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002, 51:1383-1390.
72. Nakayama M., Abiru N., Moriyama H., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
73. Tait K.F., Collins J.E., Heward J.M., et al. Evidence for a type 1 diabetes-specific mechanism for the insulin gene-associated IDDM2 locus rather than a general influence on autoimmunity. Diabet Med 2004, 21:267-270.
74. Fan Y., Rudert W.A., Grupillo M., et al. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 2009, 28:2812-2824.
75. Cloutier J.F., Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999, 189:111-121.
76. Hasegawa K., Martin F., Huang G., et al. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004, 303:685-689.
77. Bottini N., Musumeci L., Alonso A., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004, 36:337-338.
78. Dultz G., Matheis N., Dittmar M., et al. The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes. Thyroid 2009, 19:143-148.
79. Smyth D., Cooper J.D., Collins J.E., et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004, 53:3020-3023.
80. Wicker L.S., Clark J., Fraser H.I., et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 2005, 25(Suppl):29-33.
81. Friedline R.H., Brown D.S., Nguyen H., et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009, 206:421-434.
82. Ueda H., Howson J.M., Esposito L., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
83. Wicker L.S., Chamberlain G., Hunter K., et al. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol 2004, 173:164-173.
84. Mosier D.E., Gulizia R.J., Baird S.M., et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988, 335:256-259.
85. Greiner D. Use of NOD/LtSz-scid/scid mice in biomedical research. NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases 1998, 173-204. RG Landes, Austin (TX). E. Letier, M. Atkinson (Eds.).
86. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
87. King M., Pearson T., Rossini A.A., et al. Humanized mice for the study of type 1 diabetes and β cell function. Ann N Y Acad Sci 2008, 1150:46-53.
88. Atkinson M.A., Maclaren N.K., Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990, 39:933-937.
89. Zhang Z.J., Davidson L., Eisenbarth G., et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991, 88:10252-10256.
90. Harrison L.C., Dempsey-Collier M., Kramer D.R., et al. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996, 184:2167-2174.
91. Shoda L.K., Young D.L., Ramanujan S., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005, 23:115-126.
92. Hayward A.R., Shreiber M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J Immunol 1989, 143:1555-1559.
93. Chatenoud L., Thervet E., Primo J., et al. C R Acad Sci III 1992, 315:225-228. [in French].
94. Chatenoud L., Thervet E., Primo J., et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994, 91:123-127.
95. Mottram P.L., Murray-Segal L.J., Han W., et al. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl Immunol 2002, 10:63-72.
96. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
97. Parker M.J., Xue S., Alexander J.J., et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009, 58:2277-2284.
98. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
99. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
100. Vijayakrishnan L., Slavik J.M., Illes Z., et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004, 20:563-575.
101. Lenschow D.J., Ho S.C., Sattar H., et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995, 181:1145-1155.
102. Luhder F., Chambers C., Allison J.P., et al. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A 2000, 97:12204-12209.
103. Luhder F., Hoglund P., Allison J.P., et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998, 187:427-432.
104. Chen Z., Stockton J., Mathis D., et al. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A 2006, 103:16400-16405.
105. Shieh S.J., Chou F.C., Yu P.N., et al. Transgenic expression of single-chain anti-CTLA-4 Fv on β cells protects nonobese diabetic mice from autoimmune diabetes. J Immunol 2009, 183:2277-2285.
106. Hunter K., Rainbow D., Plagnol V., et al. Interactions between Idd5.1/Ctla4 and other type 1 diabetes genes. J Immunol 2007, 179:8341-8349.
107. Ivakine E.A., Fox C.J., Paterson A.D., et al. Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse. J Immunol 2005, 174:7129-7140.
108. Fox C.J., Danska J.S. Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 1998, 47:331-338.
109. McGuire H.M., Vogelzang A., Hill N., et al. Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci U S A 2009, 106:19438-19443.
110. Takenaka K., Prasolava T.K., Wang J.C., et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007, 8:1313-1323.
111. Hill N.J., Lyons P.A., Armitage N., et al. NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes 2000, 49:1744-1747.
112. Mangada J., Pearson T., Brehm M.A., et al. Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice. Diabetes 2009, 58:165-173.
113. Dai Y.D., Marrero I.G., Gros P., et al. Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering processing and presentation of pancreatic islet antigens. Diabetes 2009, 58:156-164.
114. Hung M.S., Avner P., Rogner U.C. Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6. Hum Mol Genet 2006, 15:2732-2742.
115. Vallois D., Grimm C.H., Avner P., et al. The type 1 diabetes locus Idd6 controls TLR1 expression. J Immunol 2007, 179:3896-3903.
116. Vallois D., Gagnerault M.C., Avner P., et al. Influence of a non-NK complex region of chromosome 6 on CD4+ invariant NK T cell homeostasis. J Immunol 2008, 181:1753-1759.
117. Serreze D.V., Choisy-Rossi C.M., Grier A.E., et al. Through regulation of TCR expression levels, an Idd7 region gene(s) interactively contributes to the impaired thymic deletion of autoreactive diabetogenic CD8+ T cells in nonobese diabetic mice. J Immunol 2008, 180:3250-3259.
118. Ghosh S., Palmer S.M., Rodrigues N.R., et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat Genet 1993, 4:404-409.
119. Lyons P.A., Hancock W.W., Denny P., et al. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 2000, 13:107-115.
120. Yamanouchi J., Puertas M.C., Verdaguer J., et al. Idd9.1 locus controls the suppressive activity of FoxP3+CD4+CD25+ regulatory T-cells. Diabetes 2010, 59:272-281.
121. Hamilton-Williams E.E., Wong S.B., Martinez X., et al. Idd9.2 and Idd9.3 protective alleles function in CD4+T-cells and non-lymphoid cells to prevent expansion of pathogenic islet specific CD8+T-cells. Diabetes 2010, 59:1478-1486.
122. Yamaji K., Ikegami H., Fujisawa T., et al. Evidence for Cd101 but not Fcgr1 as candidate for type 1 diabetes locus, Idd10. Biochem Biophys Res Commun 2005, 331:536-542.
123. Brodnicki T.C., Fletcher A.L., Pellicci D.G., et al. Localization of Idd11 is not associated with thymus and nkt cell abnormalities in NOD mice. Diabetes 2005, 54:3453-3457.
124. Benavides F., Perez C., Blando J., et al. The radiation-induced nackt (nkt) allele is a loss-of-function mutation of the mouse cathepsin L gene. J Immunol 2006, 176:702-703.
125. Morahan G., McClive P., Huang D., et al. Genetic and physiological association of diabetes susceptibility with raised Na+/H+ exchange activity. Proc Natl Acad Sci U S A 1994, 91:5898-5902.
126. Serreze D.V., Bridgett M., Chapman H.D., et al. Subcongenic analysis of the Idd13 locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for β 2-microglobulin. J Immunol 1998, 160:1472-1478.
127. Brodnicki T.C., Quirk F., Morahan G. A susceptibility allele from a non-diabetes-prone mouse strain accelerates diabetes in NOD congenic mice. Diabetes 2003, 52:218-222.
128. Deruytter N., Boulard O., Garchon H.J. Mapping non-class II H2-linked loci for type 1 diabetes in nonobese diabetic mice. Diabetes 2004, 53:3323-3327.
129. Koarada S., Wu Y., Fertig N., et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 2004, 173:2315-2323.
130. Morin J., Boitard C., Vallois D., et al. Mapping of the murine type 1 diabetes locus Idd20 by genetic interaction. Mamm Genome 2006, 17:1105-1112.
131. Hall R.J., Hollis-Moffatt J.E., Merriman M.E., et al. An autoimmune diabetes locus (Idd21) on mouse chromosome 18. Mamm Genome 2003, 14:335-339.
132. Hollis-Moffatt J.E., Hook S.M., Merriman T.R. Colocalization of mouse autoimmune diabetes loci Idd21.1 and Idd21.2 with IDDM6 (human) and Iddm3 (rat). Diabetes 2005, 54:2820-2825.
133. Reifsnyder P.C., Li R., Silveira P.A., et al. Conditioning the genome identifies additional diabetes resistance loci in type I diabetes resistant NOR/Lt mice. Genes Immun 2005, 6:528-538.
134. Chen J., Reifsnyder P.C., Scheuplein F., et al. " Agouti NOD": identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells. Mamm Genome 2005, 16:775-783.
135. Liston A., Lesage S., Gray D.H., et al. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 2004, 21:817-830.
136. Boulard O., Fluteau G., Eloy L., et al. Genetic analysis of autoimmune sialadenitis in nonobese diabetic mice: a major susceptibility region on chromosome 1. J Immunol 2002, 168:4192-4201.